The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global Autoinjectors Market (2nd Edition), 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    May 2018

  • Pages
    510

  • View Count
    3308

Example Insights

An updated edition is available at the following link

View 3rd edition

  1. Over 85 autoinjector devices (33% reusable / 67% disposable), including variants of individual products, are presently being manufactured by close to 20 companies. 22% of these devices are designed to deliver a variable dose of drug.
  2. 75 drug-autoinjector combination products are commercially available; amongst these, 30% received marketing approval between 2015 and 2017. Over 30 devices have been approved to cater to the rising demand for convenient delivery options for the treatment of chronic clinical conditions, such as multiple sclerosis and rheumatoid arthritis / psoriasis. These are followed by devices that are used to administer drugs for the treatment of anaphylaxis, organophosphate poisoning, migraine, growth hormone deficiency and diabetes. In addition, products are also approved for multiple other indications, such as cardiac arrhythmias, anxiety disorders, opioid overdose and systemic lupus erythematosus.
  3. Notable examples of such combination products include (no selection criteria) Auvi-Q® (Kaléo Pharma), Avonex Pen® (Biogen Idec), BYDUREON BCise (AstraZeneca), EpiPen® (Mylan / Meridian Medical Technologies), Imitrex STATdose Pen® (GlaxoSmithKline) ORENCIA® ClickJect™ (Bristol-Myers Squibb), PRALUENT® (Sanofi), TRIPLEPEN HAD (ChemProtect SK), Trulicity® (Eli Lilly / Sumitomo Dainippon Pharma) and VIBEX® Sumatriptan (Antares Pharma / Teva Pharmaceutical).
  4. A number of novel technology platforms are presently being utilized for the development of autoinjectors with advanced features, such as integrated sharps handling and controlled rate of injection. Examples of such technologies (no selection criteria) include Breeze™ technology (Nuance Designs), Depot Control technology (Union Medico), VapourSoft™ and ASI® technology (Bespak), and Rotaject™ Pressure Release technology, NIT™ technology and Pushclick™ technology (SHL Group).
  5. As a result of the widening research interest, close to 3,800 patents have been filed recently. A detailed analysis of these patents indicates that automated self-injection devices, with advanced features, are gradually becoming mainstream. Some of these features include push-on-skin release, one-handed operation, twist and mix mechanism, automatic reconstitution / priming, anti-roll, compact and sleek design, LCD screens, and Bluetooth and other connectivity platforms.  Examples of autoinjectors that have been designed to be connected to smart devices include (in alphabetical order) GROWJECTOR®2 (JCR Pharmaceuticals), Flexi-eMU (Elcam Medical), RebiSmart™ (EMD Serono) and YpsoMate® Smart (Ypsomed).
  6. A comprehensive analysis of several marketed / pipeline products suggests that over 100 drugs (not currently available in autoinjectors) are suited for delivery via autoinjectors. Most of these drugs target chronic conditions, require frequent dosing and are available for delivery via subcutaneous / intramuscular routes. We believe that these clinical candidates, if evaluated with autoinjectors, are likely to contribute substantially to the market's evolution in the mid-long term.
  7. As more drug-device combination products get approved for a diverse range of indications, we expect the market to steadily evolve over the next decade. North America (primarily the US) and Europe currently capture the largest share (close to 75%) of the market. Launch in emerging regions, such as India and China, availability of such devices for other chronic (in addition to multiple sclerosis and rheumatoid arthritis) and emergency indications (in addition to anaphylaxis), introduction of life cycle management projects for drugs nearing patent expiry are some of the opportunity areas wherein the companies are likely to focus on.

Overview

In my opinion, future market opportunity for autoinjectors is going to be considerably high in Asia Pacific, especially in India and China. This is because of more number of biosimilars being approved across these regions as well as increased size of the population that can afford and would prefer home treatment  rather than going to the local clinic for treating chronic diseases.

-Founder and Chief Executive Officer, an Israel based company

Over the years, the self-injection devices market has grown into a promising segment of the pharmaceutical industry. The domain is presently characterized by the presence of advanced technology platforms and innovative devices, offering a variety of user-friendly drug delivery solutions. One of the major driving forces behind the growth in this field is the rising incidence of chronic clinical conditions, such as rheumatoid arthritis, multiple sclerosis and diabetes. Although various pharmacological interventions are available for the treatment of these conditions, they require parenteral administration, frequent hospital visits, and are associated with multiple concerns, such as dosing and medication errors, risk of microbial contamination and needlestick injuries. However, therapies developed in combination with self-administration enabling devices have witnessed high adoption rates and have actually resulted in marked improvements in adherence to prescribed therapeutic regimens. In addition, such devices have been widely utilized in the treatment of emergency conditions such as anaphylaxis and other allergic disorders.

Since the introduction of the first autoinjector device in 1980s, their numerous benefits, such as ease-of-use, reduced chances of dosing errors, integrated safety mechanisms, and almost negligible risk of needlestick injuries, have been widely recognized among consumers and healthcare service providers. Autoinjectors are also considered to be potential life cycle management tool. Drugs nearing patent expiry can be developed for delivery using an autoinjector and retain market exclusivity as a combination product. Lyophilized Enbrel® is a well-known example; it was reformulated for delivery as a liquid formulation in the Sureclick™ autoinjector, extending its patent age by almost 11 years.

It is worth highlighting that such devices have captured the interest of several stakeholders in the industry. Various initiatives are underway to further improve safety, add better features (such as controlled-release capabilities) and make these devices more patient-friendly. In fact, between January 2013 and December 2017, close to 3,800 patents were filed in this domain, indicating the rapid pace at which research is being carried out. We believe that such efforts are likely to boost the overall growth of this market in the coming years.

 

Scope of the Report

The ‘Global Autoinjectors Market (2nd Edition), 2018-2030’ report provides a comprehensive analysis of the current state of the autoinjectors market and the likely future evolution of these devices over the next decade. The study presents an in-depth analysis of a diverse set of companies that are engaged in this domain across different regions of the globe. Amongst other elements, the report includes:

  • A review of the overall landscape of the autoinjectors market, highlighting the contributions of industry players and the key device specifications, including the primary drug container used, its volume, usability of the device, route of administration, indication and targeted drugs.
  • An in-depth patent analysis to provide an overview on how the industry has evolved from the R&D perspective. For this analysis, we looked at the patents that have been published since 2013. The analysis also highlights key information associated with these patents, such as patent type, regional distribution, CPC classification, IP litigations, emerging areas and leading industry players.
  • A comprehensive product competitiveness analysis of disposable and reusable autoinjectors taking into consideration the supplier power (based on size of employee base) and product specifications, such as route of administration, primary drug container used, mechanism of operation, dosage type and user friendliness.
  • Comprehensive profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios; each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and a comprehensive future outlook. Additionally, the report includes brief profiles of emerging players that have been established in the past decade.
  • Detailed case studies on the most commonly targeted indications, covering history of development and detailed description of the approved autoinjector products, along with their respective mechanisms of action and historical sales records. In addition, we have listed all the drugs that are currently being delivered through autoinjectors.
  • A list of marketed and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future; the candidate drugs / therapies were selected based on various parameters, such as their current route of administration, target therapeutic indication and dosage. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 900 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via autoinjector device in the future was estimated by assigning a specific score (weight) to each parameter.
  • A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for autoinjector devices. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The report provides sales forecasts for the overall autoinjectors market with detailed market segmentation on the basis of indication (anaphylaxis / multiple sclerosis / rheumatoid arthritis / migraine / diabetes / other indications), route of administration (subcutaneous / intramuscular), usability (disposable / reusable) and the geographical distribution of the market (North America / Europe / Asia Pacific / rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent three different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with David Daily (CEO and Co-founder, DALI Medical Devices), Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical) and Douglas Marenzi (Managing Director, PHC). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the autoinjectors market in the short-mid term and long term.

Chapter 3  provides a general overview of the various devices that enable self-injection of parenteral drugs, specifically focusing on autoinjectors. It features a discussion on the historical evolution of autoinjectors, along with details related to their individual components, device categories and associated manufacturing / packaging processes. In addition, it elaborates on the benefits of autoinjectors that have led to their growing adoption over the last several years. The chapter also highlights the existing concerns related to needlestick injuries and the various preventive laws that have been passed worldwide, for addressing the pressing need for introducing safety features in such devices.

Chapter 4  is an introduction to the various types of primary drug containers that are utilized in autoinjectors. It features an overview of current trends related to the use of prefilled syringes and cartridges. In addition, it lists the diverse types of primary drug containers that are available in the market, along with details on key manufacturers that are involved in the production of such containers.

Chapter 5  provides information on more than 85 autoinjectors that have already been developed or are under development. It features a comprehensive analysis of these devices based on different parameters, such as primary drug container used, volume, device usability, route of administration and other technical parameters. The chapter also includes a list of combination products that have been approved or are under development for various indications. For both disposable and reusable autoinjectors, we have presented detailed 2 X 2 matrices to compare product competitiveness, based on the supplier power (based on size of employee base) and product specifications, such as route of administration, primary drug container used, mechanism of operation, dosage type and user friendliness.

Chapter 6  provides an in-depth patent analysis, presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we looked at the patents that have been published by various players since 2013. The analysis highlights the key information associated with these patents, including patent type, regional distribution, CPC classification, IP litigations, emerging areas and the leading industry players.

Chapter 7  presents a list of therapeutic drugs that are currently available for delivery via autoinjectors. It also provides detailed case studies on the most commonly targeted indications covering history of development and detailed description of the approved autoinjector products, along with mechanism of action and historical sales of the drugs.

Chapter 8  presents a list of marketed and pipeline molecules that are likely to be considered for delivery via autoinjectors in the future. It is worth highlighting that this list was compiled based on various parameters, such as route of administration, target therapeutic indication and the current dosage regimen of the aforementioned product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 900 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via autoinjector device in the future was estimated by assigning a specific score (weight) to each parameter.

Chapter 9  provides detailed profiles of key autoinjector manufacturers. Each profile includes an overview of the company, its financial information ( if available ), overview of the autoinjector technology used, information on its product portfolio, specifications of autoinjectors devices, collaborations, recent developments and a comprehensive future outlook.

Chapter 10  provides brief profiles of certain emerging players in the autoinjectors industry. Each profile features an overview of the company, technology overview, information on product portfolio, details on the respective autoinjector devices and recent developments.

Chapter 11  presents a detailed analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market, under a comprehensive SWOT framework.

Chapter 12  presents a comprehensive market forecast analysis, highlighting the future potential of autoinjectors, till the year 2030. We have segregated the opportunity on the basis of indication (anaphylaxis / multiple sclerosis / rheumatoid arthritis / migraine / diabetes / other indications), route of administration (subcutaneous / intramuscular), usability (disposable / reusable) and the geographical distribution of the market (North America, Europe, Asia Pacific and rest of the World). Future sales and growth opportunity were estimated based on the likely adoption rates and the anticipated price of products. We have adopted a  top down  approach, backed by robust data and credible inputs from primary research, to estimates the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 13  summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14  is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with ( in alphabetical order of company name ) David Daily (CEO and Co-founder, DALI Medical Devices, Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical) and Douglas Marenzi (Managing Director, PHC).

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16  is an appendix, which provides a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Systems
3.3. Conventional Parenteral Delivery
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Prevention
3.4.3. Government Legislation for the Prevention of Needlestick Injuries
 
3.5. Self-Administration: An Emerging Trend
3.5.1 Factors Influencing Emergence of Self-Administration
3.5.1.1. Rising Burden of Chronic Diseases
3.5.1.2. Saving on Healthcare Costs
3.5.1.3. Need for Immediate Treatment in Emergency Situations
3.5.1.4. Expansion of Injectable Biologic Products
3.6. Safety Options in Self-Injectors
 
3.7 Types of Self-Injection Devices
3.7.1. Prefilled Syringes
3.7.2. Pen-Injectors
3.7.3. Needle-Free Injectors
3.7.4. Autoinjectors
3.7.5. Large Volume Wearable Injectors
 
3.8. Autoinjectors: An Important Class of Self-Injection Devices
3.8.1. Components of Autoinjectors
3.8.2. Classification of Autoinjectors
3.8.3. Manufacturing/Packaging
3.8.4. Benefits of Autoinjectors
3.8.5. Regulatory Considerations
3.8.6. Drug Device Combination Products
3.9. Concluding Remarks
 
4. PRIMARY DRUG CONTAINERS IN AUTOINJECTORS
4.1. Chapter Overview
4.2. Introduction to Primary Drug Containers
4.3 Types of Primary Drug Containers
4.3.1. Vials
4.3.2. Cartridges
4.3.2.1 Components
4.3.2.2. Types
4.3.2.3. Single Chamber Cartridges
4.3.2.4. Dual Chamber Cartridges
4.3.2.5. Applications
4.3.2.6. Drawbacks
4.3.2.7. Cartridges Available in the Market
 
4.3.3. Prefilled Syringes
4.3.3.1. Components
4.3.3.2. Classification
4.3.3.2.1. Based on Barrel Material
4.3.3.2.2. Based on Number of Chambers
4.3.3.2.3. Based on Type of Needle
4.3.3.3. Benefits
4.3.3.3.1. Over Traditional Injectable Devices
4.3.3.3.2. For Healthcare Professionals and End Users
4.3.3.3.3. For Manufacturers
4.3.3.4. Drawbacks
4.3.3.5. Prefilled Syringe Systems Available in the Market
4.3.3.5.1. Glass Prefilled Syringes
4.3.3.5.2. Plastic Prefilled Syringes
 
5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: Overall Market Overview
5.2.1. Distribution by Developers
5.2.2. Distribution by Type of Primary Drug Container
5.2.3. Distribution by Usability
5.2.4. Distribution by Dosage Type
5.2.5. Distribution by Route of Administration
5.2.6. Distribution by Volume of Container
 
5.3. Approved Combination Products: Overall Market Overview
5.3.1. Distribution by Developers
5.3.2. Distribution by Target Indication
5.3.3. Distribution by Type of Primary Drug Container
5.3.4.Distribution by Usability
5.3.5. Distribution by Route of Administration
5.3.6. Distribution by Target Drug
 
5.4. Pipeline Combination Products: Overall Market Overview
5.4.1.Grid Analysis: Distribution by Target Indication, Phase of Development and Route of Administration
 
6. PATENT ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Autoinjectors: Patent Analysis
6.3.1. Analysis by Publication Year
6.3.2. Analysis by Patent Offices
6.3.3. Analysis by CPC Classifications
6.3.4. Emerging Areas
6.3.5. Leading Players Based on Number of Patents
 
6.4. Autoinjectors: Patent Benchmarking Analysis
6.4.1. Analysis by Patent Characteristics
6.4.2. Analysis by Geography
 
6.5. Autoinjectors: Patent Valuation Analysis
6.6. Leading Patents Based on Number of Citations
 
7. CASE STUDIES
7.1. Chapter Overview
7.2. Marketed / Pipeline Drugs Being Evaluated with Autoinjectors
7.3 Case Study I: Anaphylaxis
7.3.1. Overview and Epidemiology
7.3.2. Mechanism of Action of Approved Drugs
7.3.3. History of Development of Approved Drugs
7.3.4. Autoinjectors Marketed for Anaphylaxis
7.3.4.1. Adrenaclick®
7.3.4.2. Allerject / Auvi-Q® (Formerly called e-cue™)
7.3.4.3. Anapen®
7.3.4.4. Emerade®
7.3.4.5. EpiPen® / EpiPen® Jr
7.3.4.6. Jext®
7.3.5. Autoinjectors under Development for Anaphylaxis
7.3.5.1. EpiQ
7.3.5.2. Abiliject
7.3.5.3. MiniEpi
7.3.5.4. Zeneo® Adrenaline
7.3.6. Other Dosage Forms of Approved Drugs
7.3.7 Historical Sales of Approved Drugs / Autoinjectors
 
7.4. Case Study II: Multiple Sclerosis
7.4.1. Overview and Epidemiology
7.4.2. Mechanism of Action of Approved Drugs
7.4.3. History of Development of Approved Drugs
7.4.4. Autoinjectors Marketed for Multiple Sclerosis
7.4.4.1. Avonex Pen®
7.4.4.2. PLEGRIDY Pen
7.4.4.3. Rebif® Rebidose®
7.4.4.4. RebiSmart™
7.4.4.5. Rebiject II®
7.4.4.6. ReciGen® Physioject™
7.4.4.7. BETACONNECT™
7.4.4.8. BETAJECT® Comfort / Betacomfort®
7.4.4.9. Betaject® Lite
7.4.4.10. ExtaviJect® 30G / ExtaviPro® 30G
7.4.5. Other Dosage Forms of Approved Drugs
7.4.6. Historical Sales of Approved Drugs / Autoinjectors
 
7.5. Case Study III: Migraine
7.5.1. Overview and Epidemiology
7.5.2. Mechanism of Action of Approved Drugs
7.5.3. History of Development of Approved Drugs
7.5.4. Autoinjectors Marketed for Migraine
7.5.4.1. ALSUMA®
7.5.4.2. IMITREX STATdose Pen®
7.5.4.3. Zembrace SymTouch
7.5.5. Other Dosage Forms of Approved Drugs
7.5.6. Historical Sales of Approved Drugs / Autoinjectors
 
7.6. Case Study IV: Rheumatoid Arthritis
7.6.1. Overview and Epidemiology
7.6.2. History of Development of Approved Drugs
7.6.3. Autoinjectors Marketed for Rheumatoid Arthritis
7.6.3.1. Actemra®
7.6.3.2. CIMZIA® AutoClicks® Prefilled Pen
7.6.3.3. Enbrel SureClick®
7.6.3.4. HUMIRA® Pen
7.6.3.5. ORENCIA® ClickJect™
7.6.3.6. OTREXUP™
7.6.3.7. Rasuvo® Autoinjector
7.6.3.8. SIMPONI® SmartJect® Autoinjector
7.6.4. Historical Sales of Approved Drugs / Autoinjectors
 
8. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
8.1. Chapter Overview
8.2. Marketed Molecules
8.2.1. Most Likely Candidates for Delivery Via Autoinjectors
8.2.2. Likely Candidates for Delivery Via Autoinjectors
8.2.3. Less Likely Candidates for Delivery Via Autoinjectors
8.2.4. Unlikely Candidates for Delivery Via Autoinjectors
 
8.3. Pipeline Molecules
8.3.1. Most Likely Candidates for Delivery Via Autoinjectors
8.3.2. Likely Candidates for Delivery Via Autoinjectors
8.3.3. Less Likely Candidates for Delivery Via Autoinjectors
8.3.4. Unlikely Candidates for Delivery Via Autoinjectors
 
9. KEY PLAYERS
9.1. Chapter Overview
9.2. Antares Pharma
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Product Portfolio
9.2.3.1. Autoinjectors: Product Details
9.2.3.1.1. Vibex™
9.2.3.1.2. QuickShot™
9.2.3.1.3. BigShot™
9.2.4. Collaborations
9.2.5. Recent Developments and Future Outlook
 
9.3. Company Overview
9.3.2. Financial Information
9.3.3. Technology Overview
9.3.4. Product Portfolio
9.3.4.1. Autoinjectors: Product Details
9.3.4.1.1. Syrina™
9.3.4.2. OTS™ Autoinjector
9.3.5. Collaborations
9.3.6. Recent Developments and Future Outlook
 
9.4. DALI Medical Devices
9.4.1. Company Overview
9.4.2. Product Portfolio
9.4.2.1. Autoinjectors: Product Details
9.4.2.1.1. SAN-L
9.4.2.1.2. SAN-P
9.4.2.1.3. SAN-DV
9.4.2.1.4. SAN-DV Pro
9.4.3. Collaborations
9.4.4. Recent Developments and Future Outlook
 
9.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
9.5.1. Company Overview
9.5.2. Product Portfolio
9.5.3. Autoinjectors: Product Details
9.5.3.1. Flexi-Q Disposable Autoinjectors
9.5.3.1.1. Flexi-Q PFS
9.5.3.1.2. Flexi-Q HV
9.5.3.1.3. Flexi -Q DV
9.5.3.2. Flexi-Q Reusable Autoinjectors
9.5.3.2.1. Flexi-Q mMU
9.5.3.2.2. Flexi-Q eMU-C / P
9.5.5. Collaborations
9.5.6. Recent Developments and Future Outlook
 
9.6. Jiangsu Delfu Medical Devices
9.6. Company Overview
9.6.2. Financial Information
9.6.3Product Portfolio
9.6.3.3. Autoinjectors: Product Details
9.6.3.3.1. YZ-II 3mLCartridge Digital Dose Setting GF Autoinjector
9.6.3.3.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
9.6.3.3.3. DZ-IA Auto Injector Pen
9.6.3.3.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens
9.6.3.3.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
9.6.3.3.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
9.6.3.3.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
9.6.3.3.8. YZ-II 3mL* 1u Auto Inject Pen
9.6.3.3.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
9.6.3.3.10. YZ-III Automatic Reusable Insulin Injection Pen
9.6.4. Recent Developments and Future Outlook
 
9.7. Meridian Medical Technologies
9.7.1. Company Overview
9.7.2. Technology Overview
9.7.3. Product Portfolio
9.7.3.1. Autoinjectors: Product Details
9.7.3.1.1. Antidote Treatment Nerve Agent Autoinjector (ATNAA)
9.7.3.1.2. AtroPen® Autoinjector
9.7.3.1.3. Diazepam Autoinjector C-IV
9.7.3.1.4. DuoDote® Autoinjector
9.7.3.1.5. Morphine Autoinjector C-II
9.7.3.1.6. Pralidoxime Chloride Autoinjector
9.7.3.1.8. EpiPen® / EpiPen® Jr
9.7.3.1.9. ALSUMA® / Sumatriptan Autoinjector
9.7.3.1.10. Investigational Midazolam Autoinjector
9.7.4. Recent Developments and Future Outlook
 
9.8. Owen Mumford
9.8.1. Company Overview
9.8.2. Product Portfolio
9.8.2.1. Autoinjectors: Product Details
9.8.2.1.1. Autoject® Micro
9.8.2.1.2. Autoject® 2
9.8.2.1.3. Autoject® Mini
9.8.2.1.4. Autoject Uni
9.8.2.1.5. Autoject Multi
9.8.2.1.6. Autoject® Flex
9.8.3. Collaborations
9.8.4. Recent Developments and Future Outlook
 
9.9. SHL Group
9.9.1. Company Overview
9.9.2. Product Portfolio
9.9.2.1. Two-Step Disposable Autoinjectors: Product Details
9.9.2.1.1. Amber® (Pushclick™ Technology)
9.9.2.1.2. Molly®
9.9.2.1.3. Molly® RNS
9.9.2.1.4. Molly® 2.25
9.9.2.1.5. Molly® C
9.9.2.1.6. Rotaject®
9.9.2.1.7. Bertha®
9.9.2.1.8. DAI® 2
9.9.2.1.9. Maggie®
 
9.9.2.2. Three-Step Disposable Autoinjectors: Product Details
9.9.2.2.1. DAI®
9.9.2.2.2. DAI® -RNS
9.9.2.2.3. DAI® -R
9.9.2.2.4. SDI-MIX® +NIT™
9.9.2.2.5. VSDI-MIX™
9.9.2.2.6. PPI® Injector (Rotaject™ Pressure Release Technology)
9.9.3. Collaborations
9.9.4. Recent Developments and Future Outlook
 
9.10. Union Medico
9.10.1. Company Overview
9.10.2. Technology Overview
9.10.3. Product Portfolio
9.10.3.1. Autoinjectors: Product Details
9.10.3.1.1. 45? Autoinjector
9.10.3.1.2. 45?/ S Autoinjector
9.10.3.1.3. 45?/ M Autoinjector
9.10.3.1.4. 45?/ R Autoinjector
9.10.3.1.5. Comparison of 45? Autoinjectors
9.10.3.1.6. 90?Autoinjector
9.10.3.1.7. 90?/ S Autoinjector
9.10.3.1.8. 90?/ M Autoinjector
9.10.3.1.9. 90?/ XL Autoinjector
9.10.3.1.10. SuperGrip™ Autoinjector
9.10.3.1.11. Exclusive™ Autoinjector
9.10.3.1.12. Comparison of 90? Autoinjectors
9.10.4. Recent Developments and Future Outlook
 
9.11. Ypsomed
9.11.1. Company Overview
9.11.2. Financial Information
9.11.3. Product Portfolio
9.11.3.1 Autoinjectors: Product Details
9.11.3.1.1. YpsoMate® and YpsoMate® 2.25
9.11.3.1.2. VarioJect™
9.11.3.1.3. YpsoMate® Smart
9.11.3.1.4. Comparison of Autoinjectors
9.11.4. Collaborations
9.11.5. Recent Developments and Future Outlook
 
10. EMERGING PLAYERS
10.1. Chapter Overview
10.2. AktiVax
10.3. Future Injection Technologies
10.4. Impax Laboratories (Amedra Pharmaceuticals)
10.5. Kalé o Pharma
10.6. MiniEpi
10.7. Nemera
10.8. Nuance Designs
10.9. Oval Medical Technologies
10.10. Windgap Medical
10.11. Xeris Pharmaceuticals
10.12. Zion Clinical Pharmacy
 
11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
 
12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Global Autoinjectors Market
12.2.1. Global Autoinjectors Market, 2018-2030 (By Value)
12.2.1.1. Global Autoinjectors Market: Distribution by Usability, 2018-2030 (By Value)
12.2.1.2. Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.2. Autoinjectors Market in North America, 2018-2030 (By Value)
12.2.2.1. Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (By Value)
12.2.2.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.3. Autoinjectors Market in Europe, 2018-2030 (By Value)
12.2.3.1. Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (By Value)
12.2.3.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.4. Autoinjectors Market in Asia Pacific, 2018-2030 (By Value)
12.2.4.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.2.4.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.2.5.  Autoinjectors Market in Rest of the World, 2018-2030 (By Value)
12.2.5.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.2.5.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
 
12.2.6. Global Autoinjectors Market, 2018-2030 (By Volume)
12.2.6.1. Global Autoinjectors Market: Distribution by Usability, 2018-2030 (By Volume)
12.2.6.2. Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.7. Autoinjectors Market in North America, 2018-2030 (By Volume)
12.2.7.1. Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (By Volume)
12.2.7.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.8. Autoinjectors Market in Europe, 2018-2030 (By Volume)
12.2.8.1. Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.2.8.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.9. Autoinjectors Market in Asia Pacific, 2018-2030 (By Volume)
12.2.9.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.2.9.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.2.10. Autoinjectors Market in Rest of the World, 2018-2030 (By Volume)
12.2.10.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.2.10.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
 
12.3. Autoinjectors Market for Anaphylaxis
12.3.1. Global Autoinjectors Market for Anaphylaxis, 2018-2030 (By Value)
12.3.2. Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (By Value)
12.3.2.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (By Value)
12.3.2.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.3.3. Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (By Value)
12.3.3.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (By Value)
12.3.3.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.3.4. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (By Value)
12.3.4.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.3.4.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.3.5. Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (By Value)
12.3.5.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.3.5.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
 
12.3.6. Global Autoinjectors Market for Anaphylaxis, 2018-2030 (By Volume)
12.3.7. Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (By Volume)
12.3.7.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (By Volume)
12.3.7.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.3.8. Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (By Volume)
12.3.8.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.3.8.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.3.9. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (By Volume)
12.3.9.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.3.9.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.3.10. Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (By Volume)
12.3.10.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.3.10.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
 
12.4. Autoinjectors Market for Multiple Sclerosis
12.4.1. Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (By Value)
12.4.2. Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (By Value)
12.4.2.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (By Value)
12.4.2.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.4.3. Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (By Value)
12.4.3.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (By Value)
12.4.3.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.4.4. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (By Value)
12.4.4.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.4.4.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.4.5. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (By Value)
12.4.5.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.4.5.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
 
12.4.6. Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (By Volume)
12.4.7. Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (By Volume)
12.4.7.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (By Volume)
12.4.7.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.4.8. Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (By Volume)
12.4.8.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.4.8.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.4.9. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (By Volume)
12.4.9.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.4.9.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.4.10. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (By Volume)
12.4.10.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.4.10.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
 
12.5. Autoinjectors Market for Rheumatoid Arthritis
12.5.1. Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (By Value)
12.5.2. Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (By Value)
12.5.2.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (By Value)
12.5.2.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.3. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (By Value)
12.5.3.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (By Value)
12.5.3.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.4. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (By Value)
12.5.4.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.5.4.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.5. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (By Value)
12.5.5.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.5.5.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
12.5.6. Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (By Volume)
12.5.7. Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (By Volume)
12.5.7.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (By Volume)
12.5.7.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.5.8. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (By Volume)
12.5.8.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.5.8.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.5.9. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (By Volume)
12.5.9.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.5.9.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.5.10. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (By Volume)
12.5.10.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.5.10.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
 
12.6. Autoinjectors Market for Migraine
12.6.1. Global Autoinjectors Market for Migraine, 2018-2030 (By Value)
12.6.2. Autoinjectors Market for Migraine in North America, 2018-2030 (By Value)
12.6.2.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (By Value)
12.6.2.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.6.3. Autoinjectors Market for Migraine in Europe, 2018-2030 (By Value)
12.6.3.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (By Value)
12.6.3.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.6.4. Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (By Value)
12.6.4.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.6.4.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.6.5. Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (By Value)
12.6.5.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.6.5.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
 
12.6.6. Global Autoinjectors Market for Migraine, 2018-2030 (By Volume)
12.6.7. Autoinjectors Market for Migraine in North America, 2018-2030 (By Volume)
12.6.7.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (By Volume)
12.6.7.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.6.8. Autoinjectors Market for Migraine in Europe, 2018-2030 (By Volume)
12.6.8.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.6.8.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.6.9. Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (By Volume)
12.6.9.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.6.9.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.6.10. Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (By Volume)
12.6.10.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.6.10.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
 
12.7. Autoinjectors Market for Diabetes
12.7.1. Global Autoinjectors Market for Diabetes, 2018-2030 (By Value)
12.7.2. Autoinjectors Market for Diabetes in North America, 2018-2030 (By Value)
12.7.2.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (By Value)
12.7.2.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.7.3. Autoinjectors Market for Diabetes in Europe, 2018-2030 (By Value)
12.7.3.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (By Value)
12.7.3.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.7.4. Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (By Value)
12.7.4.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.7.4.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.7.5. Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (By Value)
12.7.5.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.7.5.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
 
12.7.6. Global Autoinjectors Market for Diabetes, 2018-2030 (By Volume)
12.7.7. Autoinjectors Market for Diabetes in North America, 2018-2030 (By Volume)
12.7.7.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (By Volume)
12.7.7.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.7.8. Autoinjectors Market for Diabetes in Europe, 2018-2030 (By Volume)
12.7.8.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.7.8.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.7.9. Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (By Volume)
12.7.9.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.7.9.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.7.10. Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (By Volume)
12.7.10.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.7.10.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
 
12.8. Autoinjectors Market for Other Indications
12.8.1. Global Autoinjectors Market for Other Indications, 2018-2030 (By Value)
12.8.2. Autoinjectors Market for Other Indications in North America, 2018-2030 (By Value)
12.8.2.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (By Value)
12.8.2.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (By Value)
12.8.3. Autoinjectors Market for Other Indications in Europe, 2018-2030 (By Value)
12.8.3.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (By Value)
12.8.3.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (By Value)
12.8.4. Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (By Value)
12.8.4.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
12.8.4.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Value)
12.8.5. Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (By Value)
12.8.5.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (By Value)
12.8.5.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Value)
 
12.8.6. Global Autoinjectors Market for Other Indications, 2018-2030 (By Volume)
12.8.7. Autoinjectors Market for Other Indications in North America, 2018-2030 (By Volume)
12.8.7.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (By Volume)
12.8.7.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (By Volume)
12.8.8. Autoinjectors Market for Other Indications in Europe, 2018-2030 (By Volume)
12.8.8.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (By Volume)
12.8.8.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (By Volume)
12.8.9. Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (By Volume)
12.8.9.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (By Volume)
12.8.9.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (By Volume)
12.8.10. Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (By Volume)
12.8.10.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (By Volume)
12.8.10.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (By Volume)
 
13. CONCLUSION
13.1. Rising Incidence of Chronic Illnesses has Augmented the Demand for Devices that Enable Self-Medication
13.2. Given their Numerous Benefits, Autoinjectors have Emerged as Potent Drug Delivery Tools
13.3. Several Combination Products have Already been Approved and Many are Under Development
13.4. Majority of the Available Products are Disposable; However, Reusable Devices are Gradually Gaining Popularity
13.5. Although the Market is Led by the Well-Established Players, Start-Ups Continue to Spearhead the Innovation in this Field
13.6. Led by Several Growth Opportunities, the Market is Expected to Evolve at a Steady Pace over the Coming Decade
 
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. PHC
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Douglas Marenzi, Managing Director, PHC
 
14.3. Elcam Medical
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical
 
14.4. DALI Medical Devices
14.4.1. Company Snapshot
14.4.2. Interview Transcript: David Daily, CEO and Co-Founder, DALI Medical Devices
 
15. APPENDIX 1: TABULATED DATA
 
16.APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Popular Drug Delivery Systems
Figure 3.2  Types of Self-Injection Devices
Figure 3.3  Cartridge Based Autoinjectors v/s Prefilled Syringe Based Autoinjectors
Figure 3.4  Components of Autoinjectors
Figure 3.5  Classification of Autoinjectors
Figure 4.1   Dual Chamber Cartridges
Figure 4.2  Glass Prefilled Syringes: Advantages and Disadvantages
Figure 4.3  Plastic Prefilled Syringes: Advantages and Disadvantages
Figure 5.1  Autoinjectors: Distribution by Developers
Figure 5.2  Autoinjectors: Distribution by Type of Primary Drug Container
Figure 5.3  Autoinjectors: Distribution by Usability
Figure 5.4  Autoinjectors: Distribution by Dosage Type
Figure 5.5  Autoinjectors: Distribution by Route of Administration
Figure 5.6  Autoinjectors: Distribution by Volume of Container
Figure 5.7  Approved Combination Products: Distribution by Developers
Figure 5.8  Approved Combination Products: Distribution by Target Indication
Figure 5.9  Approved Combination Products: Distribution by Type of Primary Drug Container
Figure 5.10  Approved Combination Products: Distribution by Usability
Figure 5.11 Approved Combination Products: Distribution by Route of Administration
Figure 5.12  Approved Combination Products: Distribution by Target Drug
Figure 5.13  Pipeline Combination Products: Grid Analysis, Distribution by Target Indication, Phase of Development and Route of Administration  
Figure 6.1  Patent Portfolio: Distribution by Type of Patent
Figure 6.2  Patent Portfolio: Cumulative Distribution by Publication Year
Figure 6.3  Patent Portfolio: Distribution by Regions
Figure 6.4  Patent Portfolio: Distribution by CPC Classification Symbol
Figure 6.5  Patent Portfolio: Emerging Areas
Figure 6.6  Patent Portfolio: Distribution by Leading Assignees
Figure 6.7  Patent Portfolio: Geographical Distribution of Leading Players
Figure 6.8  Patent Portfolio: Benchmarking by Patent Characteristics
Figure 6.9  Patent Portfolio: Benchmarking by International Patents
Figure 6.10  Patent Portfolio: Distribution by Age of Patents (January 2013-October 2017)
Figure 6.11  Patent Portfolio: Valuation Analysis
Figure 7.1  Anaphylaxis: History of Development of Approved Drugs
Figure 7.2  Anaphylaxis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2012-2017
Figure 7.3  Multiple Sclerosis: History of Development of Approved Drugs
Figure 7.4  Multiple Sclerosis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2012-2017
Figure 7.5  Migraine: History of Development of Approved Drugs
Figure 7.6  Migraine: Historical Sales of Approved Drugs / Autoinjectors (USD Million), 2015-2017
Figure 7.7  Rheumatoid Arthritis: History of Development of Approved Drugs
Figure 7.8  Rheumatoid Arthritis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-2017
Figure 8.1  Likely Candidates for Delivery Via Autoinjectors: Relative Scoring of Marketed Drugs
Figure 8.2  Likely Candidates for Delivery Via Autoinjectors: Relative Scoring of Pipeline Drugs
Figure 9.1  Antares Pharma: Annual Revenues, 2012-2017 (USD Million)
Figure 9.2  Antares Pharma: Product Portfolio
Figure 9.3  Bespak: Annual Revenues, FY 2012/13-FY 2016/17 (GBP Million)
Figure 9.4  Bespak Injectables: Syrina™ Autoinjectors
Figure 9.5  DALI Medical Devices: Autoinjectors
Figure 9.6  DALI Medical Devices: Steps of Operation of SAN-L
Figure 9.7  DALI Medical Devices: Steps of Operation of SAN-P
Figure 9.8  DALI Medical Devices: Steps of Operation of SAN-DV
Figure 9.9  DALI Medical Devices: Steps of Operation of SAN-DV Pro
Figure 9.10  Elcam Medical: Product Portfolio
Figure 9.11  Elcam Medical: Flexi-Q Autoinjectors
Figure 9.12 Elcam Medical: Components of Flexi-Q PFS
Figure 9.13  Elcam Medical: Steps of Operation of Flexi-Q PFS
Figure 9.14  Elcam Medical: Components of Flexi-Q DV
Figure 9.15  Elcam Medical: Steps of Operation Flexi-Q DV
Figure 9.16  Elcam Medical: Components of Flexi-Q mMU
Figure 9.17  Elcam Medical: Components of Flexi-Q eMU
Figure 9.18  Elcam Medical: Steps of Operation of Flexi-Q mMU / Flexi-Q eMU 
Figure 9.19  Jiangsu Delfu Medical Devices: Components of Autoinjectors
Figure 9.20  Jiangsu Delfu Medical Devices: Applications of Autoinjectors
Figure 9.21  Meridian Medical Technologies: Autoinjectors Portfolio
Figure 9.22  Meridian Medical Technologies: Steps of Operation of ATNAA 
Figure 9.23  Meridian Medical Technologies: Step of Operation of Diazepam Autoinjector C-IV 
Figure 9.24  Meridian Medical Technologies: Steps of Operation of DuoDote® Autoinjector
Figure 9.25  Meridian Medical Technologies: Steps of Operation of Morphine Autoinjector
Figure 9.26  Meridian Medical Technologies: Steps of Operation of Pralidoxime Chloride Autoinjector
Figure 9.27  Meridian Medical Technologies: Steps of Operation of EpiPen®: 
Figure 9.28  Meridian Medical Technologies: Steps of Operation of ALSUMA® Autoinjector
Figure 9.29  Owen Mumford: Cartridge-Based Injection Pens
Figure 9.30 Owen Mumford: Autoinjectors Portfolio
Figure 9.31 Owen Mumford: Steps of Operation of Autoject® Micro 
Figure 9.32 Owen Mumford: Steps of Operation of Autoject®2 Autoinjector
Figure 9.33 Owen Mumford: Steps of Operation of Autoject® Mini
Figure 9.34  Owen Mumford: Steps of Operation of Autoject® Uni
Figure 9.35  Owen Mumford: Steps of Operation of Autoject® Multi
Figure 9.36  Owen Mumford: Steps of Operation of Autoject® Flex
Figure 9.37  SHL Group: Product Portfolio
Figure 9.38  SHL Group: Prefilled Syringe Based Autoinjectors
Figure 9.39  SHL Group: Cartridge Based Autoinjectors
Figure 9.40 SHL Group: Two-Step Autoinjectors
Figure 9.41  SHL Group: Steps of Operation of Two-Step Autoinjectors 
Figure 9.42  SHL Group: Three-Step Autoinjectors
Figure 9.43  SHL Group: Steps of Operation of DAI®
Figure 9.44  SHL Group: Steps of Operation of DAI®-R
Figure 9.45 SHL Group: Steps of Operation of SDI-MIX®+NIT™
Figure 9.46  Union Medico: Portfolio of 45˚ Autoinjectors 
Figure 9.47  Union Medico: Parts of 45˚/R Autoinjector
Figure 9.48 Union Medico: Types of 45˚/R Autoinjector
Figure 9.49 Union Medico: Types of 90˚ Autoinjectors
Figure 9.50 Union Medico: Components of SuperGrip™ 
Figure 9.51 Union Medico: Components of Exclusive™ 
Figure 9.52  Ypsomed: Annual Revenues, FY 2012/13-FY 2017/18 (CHF Million)
Figure 9.53  Ypsomed: Sales by Business Divisions, FY 2016/17 (CHF Million, %)
Figure 9.54  Ypsomed: Product Portfolio
Figure 9.55  Ypsomed: Steps of Operation of YpsoMate®
Figure 9.56  Ypsomed: Steps of Operation of VarioJect™
Figure 9.57  Ypsomed: Steps of Operation of YpsoMate® Smart 
Figure 11.1  Autoinjectors SWOT Analysis: Overview
Figure 11.2  Comparison of SWOT Factors: Harvey Ball Analysis
Figure 12.1  Global Autoinjectors Market, 2018-2030 (USD Million)
Figure 12.2  Global Autoinjectors Market: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.3  Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.4  Autoinjectors Market in North America, 2018-2030 (USD Million)
Figure 12.5  Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.6  Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.7  Autoinjectors Market in Europe, 2018-2030 (USD Million)
Figure 12.8  Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.9  Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.10  Autoinjectors Market in Asia Pacific, 2018-2030 (USD Million)
Figure 12.11  Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.12  Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.13  Autoinjectors Market in Rest of the World, 2018-2030 (USD Million)
Figure 12.14  Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.15  Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.16  Global Autoinjectors Market, 2018-2030 (Units, Million)
Figure 12.17  Global Autoinjectors Market: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.18  Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.19  Autoinjectors Market in North America, 2018-2030 (Units, Million)
Figure 12.20  Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.21  Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.22  Autoinjectors Market in Europe, 2018-2030 (Units, Million)
Figure 12.23  Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.24  Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.25  Autoinjectors Market in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.26  Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.27  Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.28  Autoinjectors Market in Rest of the World, 2018-2030 (Units, Million)
Figure 12.29  Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.30  Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.31  Global Autoinjectors Market for Anaphylaxis, 2018-2030 (USD Million)
Figure 12.32  Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (USD Million)
Figure 12.33  Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.34  Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.35  Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (USD Million)
Figure 12.36  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.37  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.38  Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (USD Million)
Figure 12.39  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.40  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.41  Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (USD Million)
Figure 12.42  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.43  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.44  Global Autoinjectors Market for Anaphylaxis, 2018-2030 (Units, Million)
Figure 12.45  Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (Units, Million)
Figure 12.46  Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.47  Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.48  Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (Units, Million)
Figure 12.49  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.50  Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.51  Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.52  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.53  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.54  Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (Units, Million)
Figure 12.55  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.56  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.57  Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (USD Million)
Figure 12.58  Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (USD Million)
Figure 12.59  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.60  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.61  Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (USD Million)
Figure 12.62  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.63  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.64  Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (USD Million)
Figure 12.65  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.66  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.67  Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (USD Million)
Figure 12.68  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.69  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.70  Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (Units, Million)
Figure 12.71  Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (Units, Million)
Figure 12.72  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.73  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.74  Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (Units, Million)
Figure 12.75  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.76  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.77  Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.78  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.79  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.80  Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (Units, Million)
Figure 12.81  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.82  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.83 Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (USD Million)
Figure 12.84  Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (USD Million)
Figure 12.85  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.86  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.87  Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (USD Million)
Figure 12.88  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.89  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.90  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (USD Million)
Figure 12.91  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.92  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.93  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (USD Million)
Figure 12.94  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.95  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.96  Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (Units, Million)
Figure 12.97  Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (Units, Million)
Figure 12.98  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.99  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.100  Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (Units, Million)
Figure 12.101  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.102  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.103  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.104  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.105  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.106  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (Units, Million)
Figure 12.107  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.108  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.109  Global Autoinjectors Market for Migraine, 2018-2030 (USD Million)
Figure 12.110  Autoinjectors Market for Migraine in North America, 2018-2030 (USD Million)
Figure 12.111  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.112  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.113  Autoinjectors Market for Migraine in Europe, 2018-2030 (USD Million)
Figure 12.114  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.115  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.116  Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (USD Million)
Figure 12.117  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.118  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.119  Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (USD Million)
Figure 12.120  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.121  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.122  Global Autoinjectors Market for Migraine, 2018-2030 (Units, Million)
Figure 12.123  Autoinjectors Market for Migraine in North America, 2018-2030 (Units, Million)
Figure 12.124  Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.125  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.126  Autoinjectors Market for Migraine in Europe, 2018-2030 (Units, Million)
Figure 12.127  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.128  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.129  Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.130  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.131  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.132  Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (Units, Million)
Figure 12.133  Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.134  Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.135  Global Autoinjectors Market for Diabetes, 2018-2030 (USD Million)
Figure 12.136  Autoinjectors Market for Diabetes in North America, 2018-2030 (USD Million)
Figure 12.137  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.138  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.139  Autoinjectors Market for Diabetes in Europe, 2018-2030 (USD Million)
Figure 12.140  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.141  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.142  Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (USD Million)
Figure 12.143  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.144  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.145  Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (USD Million)
Figure 12.146  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.147  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.148  Global Autoinjectors Market for Diabetes, 2018-2030 (Units, Million)
Figure 12.149  Autoinjectors Market for Diabetes in North America, 2018-2030 (Units, Million)
Figure 12.150  Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.151  Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.152 Autoinjectors Market for Diabetes in Europe, 2018-2030 (Units, Million)
Figure 12.153  Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.154  Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.155  Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.156  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.157  Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.158  Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (Units, Million)
Figure 12.159  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.160  Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.161  Global Autoinjectors Market for Other Indications, 2018-2030 (USD Million)
Figure 12.162  Autoinjectors Market for Other Indications in North America, 2018-2030 (USD Million)
Figure 12.163  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.164  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.165  Autoinjectors Market for Other Indications in Europe, 2018-2030 (USD Million)
Figure 12.166  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.167  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.168  Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (USD Million)
Figure 12.169  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.170  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.171  Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (USD Million)
Figure 12.172  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Figure 12.173  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Figure 12.174  Global Autoinjectors Market for Other Indications, 2018-2030 (Units, Million)
Figure 12.175  Autoinjectors Market for Other Indications in North America, 2018-2030 (Units, Million)
Figure 12.176  Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.177  Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.178  Autoinjectors Market for Other Indications in Europe, 2018-2030 (Units, Million)
Figure 12.179  Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.180  Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.181  Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (Units, Million)
Figure 12.182  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.183  Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Figure 12.184  Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (Units, Million)
Figure 12.185  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Figure 12.186  Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)

List of Tables

Table 3.1  Comparison of Self-Injection Devices
Table 3.2  Benefits of Autoinjectors
Table 4.1  Cartridges Available in the Market, 2018
Table 4.2  Classification of Prefilled Syringes
Table 4.3  Glass Prefilled Syringes Available in the Market, 2018
Table 4.4 Plastic Prefilled Syringes Available in the Market, 2018
Table 5.1  List of Autoinjector Devices
Table 5.2  Autoinjectors: Distribution by Dosage Type
Table 5.3 List of Approved Combination Products
Table 5.4 List of Pipeline Combination Products
Table 6.1  Patent Portfolio: CPC Symbol Definitions
Table 6.2  Patent Portfolio: Most Popular CPC Symbols
Table 6.3  Patent Portfolio: List of Top CPC Classifications
Table 6.4  Patent Portfolio: Leading Citations
Table 7.1  Marketed / Pipeline Drugs Being Evaluated with Autoinjectors
Table 7.2  Anaphylaxis: Commercially Available Autoinjectors
Table 7.3  Anaphylaxis: Other Dosage Forms of Approved Drugs
Table 7.4  Multiple Sclerosis: Commercially Available Autoinjectors  
Table 7.5  Multiple Sclerosis: Other Dosage Forms of Approved Drugs
Table 7.6  Migraine: Commercially Available Autoinjectors
Table 7.7  Migraine: Other Dosage Forms of Approved Drugs
Table 7.8  Rheumatoid Arthritis: Commercially Available Autoinjectors
Table 8.1  Marketed Molecules: Most Likely Candidates for Delivery Via Autoinjectors
Table 8.2  Marketed Molecules: Likely Candidates for Delivery Via Autoinjectors
Table 8.3  Marketed Molecules: Less Likely Candidates for Delivery Via Autoinjectors
Table 8.4  Marketed Molecules: Unlikely Candidates for Delivery Via Autoinjectors
Table 8.5 Pipeline Molecules: Most Likely Candidates for Delivery Via Autoinjectors
Table 8.6 Pipeline Molecules: Likely Candidates for Delivery Via Autoinjectors
Table 8.7  Pipeline Molecules: Less Likely Candidates for Delivery Via Autoinjectors
Table 8.8  Pipeline Molecules: Unlikely Candidates for Delivery Via Autoinjectors
Table 9.1  Antares Pharma: Recent Developments and Future Outlook
Table 9.2  Bespak: Recent Developments and Future Outlook
Table 9.3  DALI Medical Devices: Recent Developments and Future Outlook
Table 9.4  Elcam Medical: Recent Developments and Future Outlook
Table 9.5  Jiangsu Delfu Medical Devices: Autoinjectors Portfolio
Table 9.6  Jiangsu Delfu Medical Devices: Specifications of Autoinjectors
Table 9.7  Meridian Medical Technologies: Constituents of Diluents in ATNAA
Table 9.8  Meridian Medical Technologies: Comparison of AtroPen® Autoinjectors (Based on Dose Strengths)
Table 9.9  Meridian Medical Technologies: Constituents of Diluent in Diazepam Autoinjector C-IV
Table 9.10  Meridian Medical Technologies: Constituents of Diluents in DuoDote® Autoinjector
Table 9.11  Meridian Medical Technologies: Constituents of Diluent in Morphine Autoinjector C-II
Table 9.12  Meridian Medical Technologies: Constituents of Diluent in Pralidoxime Chloride Autoinjector
Table 9.13  Meridian Medical Technologies: Comparison of Autoinjectors
Table 9.14  Owen Mumford: Comparison of AutoJect®2 Variants
Table 9.15  Owen Mumford: Comparison of Autoject® 2 Variants Based on Size of the Syringe
Table 9.16  Owen Mumford: Comparison of Autoject® Mini Variants Based on Usability
Table 9.17  Owen Mumford: Features of Autoject® Flex Variants 
Table 9.18  Owen Mumford: Comparison of Autoinjectors
Table 9.19  Owen Mumford: Recent Developments and Future Outlook
Table 9.20  SHL Group: Comparison of Two-Step Disposable Autoinjectors
Table 9.21  SHL Group: Comparison of Three-Step Disposable Autoinjectors
Table 9.22 SHL Group: Recent Developments and Future Outlook
Table 9.23  Union Medico: Comparison of 45˚ Autoinjectors
Table 9.24  Union Medico: Comparison of 90˚ Autoinjectors
Table 9.25 Ypsomed: Comparison of Autoinjectors
Table 9.26  Ypsomed: Recent Developments and Future Outlook
Table 15.1  Autoinjectors: Distribution by Developers
Table 15.2  Autoinjectors: Distribution by Type of Primary Drug Container
Table 15.3  Autoinjectors: Distribution by Usability
Table 15.4  Autoinjectors: Distribution by Dosage Type
Table 15.5  Autoinjectors: Distribution by Route of Administration
Table 15.6  Autoinjectors: Distribution by Volume of Container
Table 15.7  Approved Combination Products: Distribution by Developers
Table 15.8  Approved Combination Products: Distribution by Target Indication
Table 15.9  Approved Combination Products: Distribution by Type of Primary Drug Container
Table 15.10  Approved Combination Products: Distribution by Usability
Table 15.11 Approved Combination Products: Distribution by Route of Administration
Table 15.12  Approved Combination Products: Distribution by Target Drug
Table 15.13  Patent Portfolio: Distribution by Type of Patent
Table 15.14 Patent Portfolio: Cumulative Distribution by Publication Year
Table 15.15 Patent Portfolio: Distribution by Regions
Table 15.16  Patent Portfolio: Distribution by Leading Assignees
Table 15.17 Anaphylaxis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-20115
Table 15.18 Multiple Sclerosis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-20115
Table 15.19  Migraine: Historical Sales of Approved Drugs / Autoinjectors (USD Million), 2015-20115
Table 15.20  Rheumatoid Arthritis: Historical Sales of Approved Drugs / Autoinjectors (USD Billion), 2015-20115
Table 15.21 Antares Pharma: Annual Revenues, 2015-20115 (USD Million)
Table 15.22 Bespak: Annual Revenues, FY 2015/13-FY 20115/115 (GBP Million)
Table 15.23 Ypsomed: Annual Revenues, FY 2015/13-FY 20115/18 (CHF Million)
Table 15.24 Ypsomed: Sales by Business Divisions, FY 20115/115 (CHF Million, %)
Table 15.25 Global Autoinjectors Market, 2018-2030 (USD Million)
Table 15.26 Global Autoinjectors Market: Distribution by Usability, 2018-2030 (USD Million)
Table 15.27 Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.28 Autoinjectors Market in North America, 2018-2030 (USD Million)
Table 15.29  Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.30  Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.31  Autoinjectors Market in Europe, 2018-2030 (USD Million)
Table 15.32 Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.33 Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.3 Autoinjectors Market in Asia Pacific, 2018-2030 (USD Million)
Table 15.35 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.36 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.37 Autoinjectors Market in Rest of the World, 2018-2030 (USD Million)
Table 15.38 Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.3 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.40 Global Autoinjectors Market, 2018-2030 (Units, Million)
Table 15.41 Global Autoinjectors Market: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.42 Global Autoinjectors Market: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.43 Autoinjectors Market in North America, 2018-2030 (Units, Million)
Table 15.44 Autoinjectors Market in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.45 Autoinjectors Market in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.46 Autoinjectors Market in Europe, 2018-2030 (Units, Million)
Table 15.47 Autoinjectors Market in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.48 Autoinjectors Market in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.49  Autoinjectors Market in Asia Pacific, 2018-2030 (Units, Million)
Table 15.5 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.51 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.52 Autoinjectors Market in Rest of the World, 2018-2030 (Units, Million)
Table 15.53 Autoinjectors Market in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.54 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.55 Global Autoinjectors Market for Anaphylaxis, 2018-2030 (USD Million)
Table 15.56  Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (USD Million)
Table 15.57 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.58 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.5 Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (USD Million)
Table 15.6 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.61 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.62 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (USD Million)
Table 15.63 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.64  Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.6 Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (USD Million)
Table 15.66 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.67 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.68 Global Autoinjectors Market for Anaphylaxis, 2018-2030 (Units, Million)
Table 15.69 Autoinjectors Market for Anaphylaxis in North America, 2018-2030 (Units, Million)
Table 15.70 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.71 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.72  Autoinjectors Market for Anaphylaxis in Europe, 2018-2030 (Units, Million)
Table 15.7 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.74 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.75 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2018-2030 (Units, Million)
Table 15.76 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.77 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.78 Autoinjectors Market for Anaphylaxis in Rest of the World, 2018-2030 (Units, Million)
Table 15.79 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.80  Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.81 Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (USD Million)
Table 15.82 Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (USD Million)
Table 15.83 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.84 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.85 Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (USD Million)
Table 15.86 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.87 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.88  Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (USD Million)
Table 15.89 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.90  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.91 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (USD Million)
Table 15.92  Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.93   Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.94  Global Autoinjectors Market for Multiple Sclerosis, 2018-2030 (Units, Million)
Table 15.95  Autoinjectors Market for Multiple Sclerosis in North America, 2018-2030 (Units, Million)
Table 15.96  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.97  Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.98 Autoinjectors Market for Multiple Sclerosis in Europe, 2018-2030 (Units, Million)
Table 15.99  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.100  Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.101 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2018-2030 (Units, Million)
Table 15.102  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.103  Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.104  Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2018-2030 (Units, Million)
Table 15.105 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.106 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.107 Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (USD Million)
Table 15.108 Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (USD Million)
Table 15.109 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.110 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.111 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (USD Million)
Table 15.112 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.113 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.114 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (USD Million)
Table 15.115  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.116 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.11 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (USD Million)
Table 15.118 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.119  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.120  Global Autoinjectors Market for Rheumatoid Arthritis, 2018-2030 (Units, Million)
Table 15.12 Autoinjectors Market for Rheumatoid Arthritis in North America, 2018-2030 (Units, Million)
Table 15.122  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.123  Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.124  Autoinjectors Market for Rheumatoid Arthritis in Europe, 2018-2030 (Units, Million)
Table 15.125  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.126  Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.127  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2018-2030 (Units, Million)
Table 15.128  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.129  Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.130  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2018-2030 (Units, Million)
Table 15.131  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.132  Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.133 Global Autoinjectors Market for Migraine, 2018-2030 (USD Million)
Table 15.134 Autoinjectors Market for Migraine in North America, 2018-2030 (USD Million)
Table 15.135 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.136  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.137  Autoinjectors Market for Migraine in Europe, 2018-2030 (USD Million)
Table 15.138  Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.13  Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.140  Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (USD Million)
Table 15.141 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.142  Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.143  Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (USD Million)
Table 15.144 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.14 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.146 Global Autoinjectors Market for Migraine, 2018-2030 (Units, Million)
Table 15.147 Autoinjectors Market for Migraine in North America, 2018-2030 (Units, Million)
Table 15.148 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.149  Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.15 Autoinjectors Market for Migraine in Europe, 2018-2030 (Units, Million)
Table 15.151 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.152 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.153 Autoinjectors Market for Migraine in Asia Pacific, 2018-2030 (Units, Million)
Table 15.15 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.155 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.156 Autoinjectors Market for Migraine in Rest of the World, 2018-2030 (Units, Million)
Table 15.157 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.158 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.159 Global Autoinjectors Market for Diabetes, 2018-2030 (USD Million)
Table 15.160 Autoinjectors Market for Diabetes in North America, 2018-2030 (USD Million)
Table 15.161 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.162 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.16 Autoinjectors Market for Diabetes in Europe, 2018-2030 (USD Million)
Table 15.164 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.165 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.166 Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (USD Million)
Table 15.167 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.168 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.169 Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (USD Million)
Table 15.170 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.171 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.172 Global Autoinjectors Market for Diabetes, 2018-2030 (Units, Million)
Table 15.173 Autoinjectors Market for Diabetes in North America, 2018-2030 (Units, Million)
Table 15.174 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.175 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.176 Autoinjectors Market for Diabetes in Europe, 2018-2030 (Units, Million)
Table 15.177 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.178 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.179 Autoinjectors Market for Diabetes in Asia Pacific, 2018-2030 (Units, Million)
Table 15.180 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.18 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.182 Autoinjectors Market for Diabetes in Rest of the World, 2018-2030 (Units, Million)
Table 15.183 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.184 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.18 Global Autoinjectors Market for Other Indications, 2018-2030 (USD Million)
Table 15.186 Autoinjectors Market for Other Indications in North America, 2018-2030 (USD Million)
Table 15.18 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 15.18 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.189 Autoinjectors Market for Other Indications in Europe, 2018-2030 (USD Million)
Table 15.190 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 15.191 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.192 Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (USD Million)
Table 15.193 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 15.194 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.195 Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (USD Million)
Table 15.196 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (USD Million)
Table 15.197 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (USD Million)
Table 15.198 Global Autoinjectors Market for Other Indications, 2018-2030 (Units, Million)
Table 15.199 Autoinjectors Market for Other Indications in North America, 2018-2030 (Units, Million)
Table 15.200 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Europe, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.205 Autoinjectors Market for Other Indications in Asia Pacific, 2018-2030 (Units, Million)
Table 15.206 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by  Usability, 2018-2030 (Units, Million)
Table 15.207 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2018-2030 (Units, Million)
Table 15.20 Autoinjectors Market for Other Indications in Rest of the World, 2018-2030 (Units, Million)
Table 15.209 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2018-2030 (Units, Million)
Table 15.210 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2018-2030 (Units, Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. AbbVie
  2. Ablynx 
  3. Acceleron Pharma
  4. Allergan
  5. Acuitas Therapeutics
  6. Aesica Pharmaceuticals
  7. Laboratoire AGUETTANT  
  8. AktiVax
  9. Alexion Pharmaceuticals
  10. ALK-Abelló A/S 
  11. Allergy Therapeutics 
  12. Alnylam Pharmaceuticals
  13. Alphamab Jilin 
  14. Alvogen
  15. AMAG Pharmaceuticals 
  16. Amedra Pharmaceuticals 
  17. Amgen 
  18. Amneal Pharmaceuticals
  19. Amylin Pharmaceuticals
  20. Androsystems
  21. AnGes  
  22. Antares Pharma 
  23. Antaros Medical
  24. Aptar Pharma
  25. Arrowhead Pharmaceuticals
  26. Arte 
  27. Arteaus Therapeutics 
  28. Asahi Kasei Pharma 
  29. Ascendis Pharma
  30. Astellas Pharma
  31. AstraZeneca
  32. Axon Neuroscience 
  33. Bay City Capital
  34. Bayer 
  35. BD Medical
  36. Beijing Dongfang Biotech 
  37. Bespak 
  38. Betta Pharmaceuticals 
  39. Biocad
  40. Biocon
  41. Biogen 
  42. BioGenCell 
  43. BioGene Pharmaceutical
  44. BioLineRx
  45. BioMarin Pharmaceutical
  46. Bioprojet Pharma
  47. Boehringer Ingelheim
  48. Boston Pharmaceuticals
  49. Bristol-Myers Squibb 
  50. Caladrius Biosciences
  51. Cambridge Consultants
  52. Celgene
  53. Celltrion Healthcare
  54. ChemProtect SK
  55. Chugai Pharmaceutical  
  56. CinnaGen
  57. Connected Health Services
  58. Consort Medical 
  59. Corvidia Therapeutics
  60. Creare 
  61. Crossject
  62. CSL Behring
  63. CuraVac
  64. CytoDyn 
  65. Daikyo Seiko
  66. DALI Medical Devices
  67. Deerfield Management 
  68. DiaMedica Therapeutics
  69. Disetronic Holding 
  70. Dr. Reddy's Laboratory
  71. Eiger BioPharmaceuticals
  72. Eisai 
  73. Elcam Medical
  74. Elli Lilly
  75. EMD Serono
  76. Emergent BioSolutions
  77. Ferring Pharmaceuticals 
  78. Future Injection Technologies
  79. Galderma R&D
  80. Genentech
  81. Gerresheimer
  82. Gilead Sciences
  83. GlaxoSmithKline
  84. Globe Medical Tech 
  85. HAL Allergy Group
  86. Hanmi Pharmaceuticals
  87. Haselmeier 
  88. Hoffmann-La Roche 
  89. Hospira
  90. Idera Pharmaceuticals 
  91. Immune Response BioPharma 
  92. Immunex 
  93. Impax Laboratories
  94. Injectech
  95. Inmunotek 
  96. Innovent Biologics 
  97. Ionis Pharmaceuticals 
  98. Ipsen
  99. Janssen Biotech
  100. JCR Pharmaceuticals
  101. Jerini 
  102. Jiangsu Delfu Medical Device 
  103. Kaléo 
  104. Kang Stem Biotech 
  105. KeyBioscience 
  106. King Pharmaceuticals 
  107. Kisling
  108. Kyowa Hakko Kirin
  109. LEO Pharma 
  110. Lineage Therapeutics 
  111. LyoGo
  112. M3 Biotechnology
  113. Meda Pharmaceuticals
  114. Medac Pharma 
  115. Medeca Pharma
  116. Medicom Innovation Partner
  117. Medimop Medical Projects 
  118. MedPro Group
  119. Merck 
  120. Meridian Medical Technologies
  121. Mérieux Développement 
  122. MGlas
  123. MiniEpi
  124. Momenta Pharmaceuticals
  125. Mylan 
  126. Nemera
  127. NGM Biopharmaceuticals
  128. Nipro PharmaPackaging
  129. Nordic Bioscience 
  130. Novartis
  131. Novo Nordisk
  132. Nuance Designs
  133. Ompi - Stevanato Group
  134. OneWorld DMG 
  135. OPKO Biologics
  136. Otsuka Pharmaceutical
  137. Oval Medical Technologies
  138. Owen Mumford
  139. PA Consulting Group 
  140. Palatin Technologies 
  141. Palmetto Partners
  142. Pfizer
  143. PHC 
  144. Plas-Tech Engineering
  145. Pluristem Therapeutics
  146. PRA Health Sciences
  147. ProJect Pharmaceutics
  148. Promius Pharma 
  149. QuiO
  150. RaviMed
  151. Redmile Group
  152. Regeneron Pharmaceuticals
  153. REMD Biotherapeutics
  154. Revolutions Medical
  155. Rhythm Pharmaceuticals
  156. Roselabs Bioscience
  157. Samsung Bioepis
  158. Sandoz
  159. Sanofi
  160. Santarus 
  161. Schott
  162. Schreiner MediPharm 
  163. Serina Therapeutics
  164. Shandong Weigao
  165. Shire
  166. SHL Group
  167. SiliCycle
  168. SiO2 Medical Products
  169. SK Chemicals 
  170. SKINSORB Cosmetics
  171. SMC
  172. Stealth BioTherapeutics 
  173. Sumitomo Dainippon Pharma
  174. Sun Pharmaceutical
  175. Survival Technologies
  176. Synthon Hisapania
  177. TaiMed Biologics
  178. Taisei Kako
  179. Takeda Pharmaceutical 
  180. Terumo 
  181. Teva Pharmaceutical Industries
  182. The Medical House 
  183. The Medicines Company
  184. Thinfilm Electronics 
  185. Tolmar
  186. Tonghua Dongbao Pharmaceutical 
  187. TSH Biopharm 
  188. UCB Biopharma
  189. Ultragenyx Pharmaceutical 
  190. Uman Pharma
  191. Unilife 
  192. Union Medico
  193. US Medical Instruments 
  194. US WorldMeds
  195. Valeant Pharmaceuticals International
  196. Vetter Pharma
  197. ViiV Healthcare 
  198. Vitaeris
  199. West Pharmaceutical Services
  200. Wild Basin Investments 
  201. Windgap Medical
  202. Xeris Pharmaceuticals
  203. Ypsomed 
  204. Zafgen
  205. Zion Clinic Pharmacy 
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com